T he peptide originally identified as natural killer (NK) transcript 4 1 was renamed as interleukin (IL)-32 after being shown to possess proinflammatory characteristics 2 . As research progressed, several isoforms of IL-32 were described. Initially, four isoforms (IL-32a, b, c and d) were found to derive from alternative splicing of a single gene. Among these, IL-32c is the longest and offers the strongest biological activity 2, 3 . Two additional isoforms have recently been identified, IL-32e and f, but these isoforms are not ubiquitously expressed except in T cells 4 . Given that IL-32 has been identified only in higher mammals, in which adaptive immunity is highly developed 2 , it is tempting to speculate that the role of IL-32 is relevant to adaptive immunity itself or the transition from innate to adaptive immunity in the context of bacterial or virus infection.
IL-32 has been shown to induce various inflammatory cytokines, such as tumor necrosis factor (TNF)a, IL-1, IL-6 and IL-8. Due to such proinflammatory properties, IL-32 has been considered to play a key role in innate immunity host-defense and the development of chronic inflammatory diseases, including mycobacterial 5, 6 or viral infection [7] [8] [9] , rheumatoid arthritis (RA), inflammatory bowel disease (IBD) 10 , and chronic obstetric pulmonary disease 11 . Several publications have recently reported that IL-32 exerts a host defensive role, particularly against viral infections. Patients infected with human immunodeficiency virus (HIV) show elevated IL-32 serum levels, and silencing endogenous IL-32 increases HIV p24 production 8, 12 . Moreover, blockade of IFN-a/IFN-b bioactivity in IL-32c-stimulated U1 macrophages results in enhanced production of HIV, demonstrating that the antiviral activity of IL-32c is applied through these type I interferons (IFNs) 12 .
Mounting evidence regarding upstream signaling regulators for IL-32 production has been accumulating in the literature [13] [14] [15] [16] [17] . However, signaling pathways downstream of IL-32 have yet to be fully elucidated. We have previously shown that IL-32-induced TNFa production is mediated through nuclear factor (NF)-kB and extracellular signal-regulated protein kinase (ERK)1/2 mitogen-activated protein kinase (MAPK) in RAW264.7 cells 18 , but details of the IL-32 signaling cascade to ERK1/2 and NFkB activation have yet to be elucidated. Synergistic interactions of IL-32 with ligands of pattern recognition receptors (PRRs) such as nucleotide oligomerization domain (NOD)1/2 and toll-like receptor (TLR)2/4 have been described in a number of reports [18] [19] [20] , whereas IL-32 can substantially trigger the TLR signaling cascade without any PRR ligand 18, 20 . Protease-activated receptor 2 (PAR2) is a potential candidate molecule capable of explaining IL-32 bioactivity including use of TLR signaling and type I IFN-mediated antiviral immunity. PAR2 has been shown to induce TNFa and type I IFN, predominantly through a myeloid differentiation factor 88 (MyD88)-independent TLR signaling pathway, that is a Toll/ IL-1 receptor (TIR)-domain-containing adapter-inducing IFN-b (TRIF) signaling pathway, which is reportedly implicated in delayed kinetics of TLR4-mediated NF-kB activation.
PAR2 is a seven-transmembrane G protein-coupled receptor and acts as a PRR, sensing not only bacterial serine proteases, but also autologous serine proteinase, proteinase-3 (PR3) in the context of inflammation and infection. PR3 reportedly binds to IL-32 21 and is capable of stimulating PAR2 [22] [23] [24] . Since membrane-bound PR3 expression increases in chronic inflammatory diseases such as vasculitis and RA 25 , activation of PAR2 by PR3 may occur on the cell surface. Among six isoforms of IL-32, IL-32c is the isoform most likely to have the ability to be bound to membrane-bound PR3 and subsequently activate PAR2. The present study examined the extracellular biological function of IL-32c through interactions with PR3 and PAR2, which ultimately resulted in triggering PAR2-TRIF signaling axis, and proposes a potential role of IL-32 in the transition from innate to adaptive immunity.
Results
Lipopolysaccharide (LPS) is the strongest inducer of IL-32c among multiple pathogen-associated molecular patterns (PAMPs) recognized by TLRs. While unstimulated THP-1 cells did not constitutively express IL-32 mRNA, either LPS-or zymosan-stimulated THP-1 cells expressed significantly high levels of IL-32 mRNA and IL-32 protein (Fig. 1a) . On the other hand, little or no expression of IL-32 mRNA was apparent when THP-1 cells were stimulated with other TLR ligands, such as poly (I:C), imquimod and CpGDNA. The expression level of IL-32 and the amount of IL-32 protein induced by LPS was increasing, at least over the first 24 h following LPSstimulation (Fig. 1b) .
Both IL-32c and LPS can solely induce TNFa and IFN-b mRNA expression. Both IL-32c and LPS were capable of independently stimulating TNFa mRNA expression and protein production by THP-1 cells, with much higher levels for LPS than for IL-32c. Interestingly, LPS-induced TNFa mRNA expression and protein production demonstrated double peaks during the course of 48 h stimulation, whereas IL-32c-induced TNFa mRNA expression and protein production displayed a single peak (Fig. 2a) . LPS and IL-32c Figure 1 | LPS is the strongest inducer of IL-32 among multiple PAMPs. THP-1 cells were cultured with LPS (100 ng/ml or 1 mg/ml), zymosan (10 or 100 mg/ml), poly (I:C) (10 or 100 mg/ml), imiquimod (10 or 100 mg/ml), and CpG-B DNA (10 or 100 mM) for 6 h, then levels of IL-32 mRNA and protein in culture supernatant were measured by real-time PCR or specific ELISA. LPS and zymosan significantly induced IL-32 at both mRNA and protein levels, whereas other ligands did not (a). Temporal changes in the level of IL-32 induced by LPS (100 ng/ml) were measured at both mRNA and protein levels by real-time PCR or ELISA (b). The expression level of IL-32 mRNA and protein induced by LPS was increasing at least over the first 24 h following LPS stimulation. Values are expressed as mean 6SD for four independent experiments. *p , 0.05 and **p , 0.01. also stimulated THP-1 cells to express IFN-b mRNA and produce IFN-b protein with comparable levels, and a bimodal expression or production pattern was again observed particularly for LPSstimulation (Fig. 2b) . When THP-1 cells were transfected with siRNA targeting IL-32c, double peaks of LPS-induced TNFa expression and production changed to a single peak, while each control did not show such effect (Fig. 2c) , suggesting that the second peak observed at 12 h was attributable to the effects of LPS-induced IL32c. As for IFN-b, the first peak was observed at 6 h after IL-32c stimulation; thereafter, the expression and production level was constant without an apparent second peak until 48 h, suggesting that the second peak of IFN-b is attributable to LPS-induced IL32c (Fig. 2d) .
Activation of PR3 is indispensable for IL-32c-induced TNFa and IFN-b mRNA expression. Although PR3, a serine protease, reportedly acts as a binding protein for IL-32 23 , whether IL-32c modulates the serine protease activity of PR3 remains unclear. PR3 activity in IL-32c-stimulated THP-1 cells was measured by FLISP, which is an experimental assay of intracellular chymotrypsinlike enzyme activity in living cells by using fluorescent-Labeled inhibitors of serine proteases. Photomicrography and fluorescence spectrometry revealed that addition of IL-32c increased the fluorescent intensity in cultured THP-1 cells, indicating increased serine protease activity (Fig. 3a, b) . Phenylmethanesulfonyl fluoride (PMSF), a general serine/cysteine protease inhibitor, significantly decreased the mRNA expressions and protein production of both TNFa and IFN-b induced by IL-32c (Fig. 3c) . When THP-1 cells were transfected with siRNA targeting PR3, levels of IL-32c-induced TNFa and IFN-b declined markedly, while transfection with control siRNA did not show such effect, indicating that PR3 knockdown might mostly cancel IL-32-induced TNFa and IFN-b (Fig. 3d) . PR3 thus appears indispensable for mRNA expression and protein production of TNFa and IFN-b in response to IL-32c.
PAR2-TRIF and PAR2-Ras-Raf-1 pathways are chiefly responsible for transduction of IL-32c signal to TNFa and IFN-b mRNA expression. As PAR2 has been shown to be activated by serine proteases such as PR3, interactions between IL-32c and PAR2 or relevant downstream molecules were examined. IL-32c-stimulated TNFa and IFN-b were completely abrogated when THP-1 cells were transfected with siRNA targeting PAR2, while transfection with control siRNA did not exert such effect (Fig. 4a) . GW5074, an inhibitor of Raf-1, significantly diminished TNFa expression at both mRNA and protein levels by THP-1 cells, whereas mRNA expression or protein production of IFN-b was unchanged (Fig. 4b) . Transfection of siRNA targeting TRIF resulted in reduced mRNA expression and protein production of both TNFa and IFN-b by THP-1 cells in response to IL-32c, whereas no significant effect was observed with siRNA targeting TRIF-related adaptor molecule (TRAM) (Fig. 4c) . These results indicate that IL-32c induced TNFa using the two signaling arms of PAR2, including the Ras-Raf axis and TRIF-TRAF6 axis, and induced IFN-b mRNA expression using only the TRIF axis.
Neutralization of TNFa markedly increases levels of IL-32c-induced IFN-b. As TNFa is reportedly an inducer of type I IFN 26 , the interrelationship between TNFa and IFN-b (both of which can be induced by IL-32c) was assessed using etanercept, a soluble TNFa receptor fusion protein used widely for treating inflammatory www.nature.com/scientificreports arthropathy and inflammatory bowel disease in humans. Etanercept prominently upregulated the level of IFN-b mRNA and production induced by IL-32c (Fig. 5a , p , 0.01). This indicated that TNFa induced by IL-32c rather suppressed IFN-b expression induced by IL-32c. Meanwhile, since type I interferon has been reported to suppress the induction of TNFa 27 , Mouse Monoclonal Antibody against Human Interferon-Alpha/Beta Receptor 1 (IFNAR) and IL-32c were simultaneously added to THP-1 cells in culture. This combination of IFNAR did not affect the level of TNFa mRNA expression and protein production induced by IL-32c, whereas the level of TNFa mRNA and protein production constitutively expressed in THP-1 cells was increased by addition of IFNAR (Fig. 5b, c) . Collectively, in THP-1 cells, IFN-b was capable of suppressing constitutive TNFa, but did not influence TNFa induced upon IL-32c-stimulation.
Protein kinase C (PKC) subtypes regulate expression of TNFa and IFN-b mRNA induced by IL-32c. PKC is reportedly involved in TLR and PAR2 signaling pathways 28, 29 . Several PKC isotypes have been identified, including conventional PKC (a,b, and c), novel PKC (d, e, et al.) and atypical PKC (f, et al.). Bisindolylmaleimide (BIS), a pan-PKC inhibitor, and rottlerin, a specific inhibitor for PKCd, significantly downregulated IL-32c-induced TNFa and IFN-b (p , 0.05), whereas Gö6976, a PKCa/b inhibitor, did not (Fig. 6a) . Likewise, siRNA against PKCd decreased levels of IL-32c-induced TNFa and IFN-b (p , 0.05), whereas siRNA targeting PKCe conversely increased levels of these cytokines (Fig. 6b, p , 0.05 ). TRAM adaptor with GOLD domain (TAG) is a splicing variant of TRAM and is known as a TRAM inhibitor 30, 31 . IL-32c stimulated mRNA expression of TAG, and PMA markedly augmented TAG expression (Fig. 6c) . Discussion Over the 48 h stimulation with LPS, mRNA expressions of both TNFa and IFN-b were upregulated in THP-1 cells with an apparently bimodal pattern, although the second peak of these expressions disappeared upon suppression of IL-32c by RNA interference. Given that LPS was a potent inducer of IL-32c among a variety of PAMPs, this second peak appears attributable to LPS-induced IL32c. Actually, downstream signaling of LPS via TLR4 has been reported to use two distinct arms, MyD88 and TRIF. Both signaling pathways commonly mediate activation of NF-kB and MAPKs, with MyD88 for early-phase activation 32 and TRIF for late-phase activation 33, 34 . According to most studies in the literature, the expression pattern of TNFa is bimodal due to MyD88 and TRIF signaling arms, and TNFa expression ordinarily terminates within 6 h after LPS stimulation. We therefore believe that bimodal TNFa expression persisting over 48 h after LPS-stimulation is attributable to LPSinduced IL-32c.
PR3 has been reported as a binding protein of IL-32 21 , and has been speculated to activate PAR2, which may play a key role in exhibiting IL-32 bioactivity 35 . Recent works have clarified in vivo roles of PAR2 as a sensor for both endogenous and exogenous serine proteases to maintain immune homeostasis 36, 37 . However, no reports have dealt with the detailed interactions between IL-32, PR3, and PAR2. The present study demonstrated that IL-32c clearly upregulated serine protease activity, and expressions of both TNFa and IFN-b mRNA induced by IL-32c were canceled by serine/cysteine protease inhibitor, PMSF or siRNA targeting PR3. These two cytokine expressions were also completely blocked by siRNA targeting PAR2. Increased PR3 activity and subsequent activation of PAR2 are thus necessary for IL-32c to exhibit its biological activities (Fig. 7) . Past evidence regarding PR3-PAR2 interactions 23, 24 and the receptorligand relationship of IL-32 and PR3 21 corroborate our results. Recently, one investigator has reported that IL-32a and b are bound to integrin-aVb3 with their own RGD motif, so integrin represents a candidate for the receptor of intracellular IL-32 38 . In our experimental condition with THP-1 cells, however, cyclo-RGDfV, an inhibitor of integrin-aVb3, did not affect the bioactivity of exogenous IL-32c (data not shown; Fig. S5 ). Previous studies have shown that the Ras-Raf signaling pathway and TRIF pathway are important for downstream signaling of PAR2, both of which ultimately lead to induction of TNFa (Fig. 7 ) [39] [40] [41] . In the present study, GW5074, the specific inhibitor for Raf-1, and siRNA targeting TRIF significantly diminished biological activities of IL-32c, reflecting the existence of IL-32-PAR2 interactions in THP-1 cells. The putative IL-32c-PAR2 axis is further supported by the fact that increased intracellular calcium levels following IL32c stimulation 42 are compatible with the ability of PAR2 to cause intracellular calcium mobilization via G-protein [39] [40] [41] . Without IL-32c-induced TNFa production, IL-32c might induce type I interferon more prominently, since our results revealed that etanercept markedly potentiated IFN-b mRNA expression induced by IL-32c. On the other hand, addition of IFNAR did not affect TNFa production induced by IL-32c, but instead increased levels of TNFa constitutively produced by THP-1 cells. In the context of bacterial or viral infection, the increment of TNFa expression is a very early event, followed by gradual increases in the level of type I interferon with decreasing levels of TNFa. Type I interferon has been shown to be essential for both Th1 cell polarization and antibody production (i.e., Th2), thus shaping adaptive immunity. Taken together with the present results that LPS is the strongest inducer of IL-32c and that LPS-induced IL-32c ultimately induces type I interferon production, IL-32c appears to play a role in the transition from innate immunity to antigen-specific adaptive immunity in combination with IL-1, IL-6, IL-12, IL-18 and IL-23. TAG, a splice variant of TRAM, acts like a dominant-negative inhibitor of TRAM and has been reported to negatively regulate the TRAM-TRIF pathway 31 . IL-32c-induced TAG presumably blocks the TRAM-TRIF axis and favors the PAR2-TRIF axis, corroborating the fact that IL32c-induced TNFa and IFN-b mRNA expressions were predominantly mediated by TRIF, but not by TRAM in our study. When TLR4 is stimulated with LPS, IL-32c-induced TAG might contribute to termination of the LPS-TLR4-TRAM-TRIF axis and instead, augment the IL-32c-PAR2-TRIF axis for the transition from innate to adaptive immunity.
The significance of the IL-32c-PAR2-TRIF axis should be also recognized as an alternative signaling pathway to the LPS-TLR4-TRIF axis in shaping adaptive immunity. Potential situations with bacterial infection occasionally endanger the LPS-TLR4 system, in what has been perceived as an endotoxin tolerance. Endotoxin tolerance has been shown to suppress LPS-inducible TLR4-TRIF and TRIF-TRAF associated NF-kB activator (TANK)-binding kinase (TBK)1 associations followed by inactivation of IRF-3 43 . Cario et al. reported that trypsin-like proteases derived from bacteria cause extensive proteolysis of myeloid differentiation factor 2 (MD-2) which contains multiple trypsin cleavage sites, leading to impaired LPS recognition of TLR4 44 . Dysfunction of the TLR4 signaling pathway ultimately attenuates MyD88-and TRIF-dependent proinflammatory cytokine expression by macrophages, with unchanged or increased production of anti-inflammatory cytokines, and increased incidence of secondary infections 45 . Impaired trafficking of TLR4 occasionally influences recruitment of TRIF. TLR4 mobilization from endosomes to phagosomes is a process necessary for the recruitment of TRIF and subsequent induction of type I interferon, whereas PAR2 recruits TRIF on the cell surface 46 . PAR2-TRIF engagement is advantageous to certain bacterial infection with disrupted endocytosis and escape from host defenses 47 . Furthermore, IL-32c extracellularly modulates PAR2 by binding to PR3. The IL-32-PAR2-TRIF axis might thus be evolutionarily gained against the above-mentioned multiple types of endotoxin tolerances, including inactivated TBK1, trypsin cleavage of MD-2, and impaired TLR4 trafficking.
PAR2 couples to and activates G-proteins and leads to induction of canonical PLC/PKC signaling 29, 38 . Among various PKC subtypes, PKCd is reportedly involved in TLR signaling through its interaction with TIR domain containing adaptor protein (TIRAP), upstream of MyD88 28, 48 . PKCe phosphorylates TRAM in the presence of MyD88 49 . Our study revealed that siRNA targeting PKCd downregulated IL-32c-induced TNFa and IFN-b; in contrast, siRNA targeting PKCe led to upregulation of these cytokines. Both TLR4 and PAR2 commonly use TRIF for each downstream signaling, suggesting the feasibility of competitive recruitment of TRIF between these two PRRs. Inhibition of PKCd might result in activation of PKCe, increasing the proportion of TRIF associated with TLR4 but not with PAR2, and subsequently reducing the levels of IL-32c-induced TNFa and IFN-b. In contrast, inhibition of PKCe increases the proportion of TRIF associated with PAR2, followed by increment of IL-32c-induced TNFa and IFN-b. PKC subtypes including d and e therefore control the balance between the TLR4-TRIF and PAR2-TRIF axes, and PKCd in particular favors the PAR2-TRIF axis through increased expression of TAG (Fig. 7) .
In summary, once LPS from Gram-negative bacteria is recognized by TLR4, TLR4-MyD88 pathway is triggered, and early-phase TNFa expression is initiated through the activation of NF-kB and MAPKs (Fig. 7) . As for differential activation of PKC isoforms, PKCd is activated first, followed by PKCe, resulting in activation of the TRAM-TRIF pathway to contribute to late-phase TNFa expression. Concurrently, IL-32c induced by TLR4 agonist such as LPS binds to PR3 and activates PAR2. The PAR2-Ras and -TRIF pathways induce TNFa expression and the latter pathway particularly induces type I interferon expression via IRF3/7. At that time, PKCd is activated and PKCe is suppressed 50 and TAG is synthesized to terminate TLR4-TRIF signaling, whereby TRIF is preferentially recruited to PAR2 instead. Following LPS-induced TNFa expression mainly through TLR4, LPS-induced IL-32c-PAR2 signaling gradually increases type I interferon expression to translate innate to adaptive immunity, or to terminate the cascade of LPS-induced acute inflammation. Given that IL-32 exists only in higher mammals, the IL-32-PAR2-TRIF axis may have been gained during the evolution of mammalian immune systems in order to function not only as an extracellular sensor of bacterial and autologous proteases, but also as an interface between innate and adaptive immunity.
Methods
Reagents. Recombinant human IL-32c protein (rIL-32c) was purchased from R&D Systems (Minneapolis, MN, USA). Human rIL-32c was tested for endotoxin contamination with Limulus ESII test, which was purchased from Wako Pure Chemical Industries (Osaka, Japan). LPS from Escherichia coli 0111:B4, zymosan A from Saccharomyces cerevisiae, poly (I:C), PMSF, PMA, Gö6976 and rottlerin were purchased from Sigma-Aldrich (St. Louis, MO, USA). Imiquimod, TLR7 agonist, was purchased from Merck Millipore (Billerica, MA, USA). CpG-B DNA (human/ mouse), a TLR9 agonist, was purchased from Hycult Biotech (Uden, the Netherlands). GW5074 was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Etanercept was obtained from Wyeth Japan (Tokyo, Japan). IFNAR was purchased from Pestka Biomedical Laboratories (Piscataway, NJ, USA). BIS was purchased from Cell Signaling Technology Japan (Tokyo, Japan). PMSF, BIS, Gö6976, rottlerin and GW5074 were dissolved in 100% dimethyl sulfoxide (DMSO) at 100 mM and stored in aliquots at 230uC. Before use in cell culture, these agents were diluted with the medium to a final DMSO concentration of #0.05%.
Real-time polymerase chain reaction (PCR) analysis. Total RNAs were isolated from each sample by RNAiso plusH (Takara Bio, Kyoto, Japan), and cDNAs were synthesized from total RNAs using a PrimeScript RTH reagent kit (Takara Bio). Realtime PCR was performed using SYBR Premix ExTaq IIH (Takara Bio) with a DICE thermal cyclerH (Takara Bio), according to the instructions from the manufacturer. Results were normalized to glyceraldhyde-3-phosphate dehydrogenase (GAPDH) as the fold change compared with samples. The primer sequences used in this study are presented in Table 1 .
ELISA. IL-32-specific enzyme-linked immunosorbent assay (ELISA) (Human Interleukin 32 ELISA Kit) was purchased from Cusabio (Wuhan, China), and TNFaspecific ELISA (Quantikine Human TNFa) was purchased from R&D Systems (Minneapolis, MN, USA). IFN-b-specific ELISA (VeriKine-HS Human Interferon Beta Serum ELISA Kit) was purchased from PBL Interferon Source (Piscataway, NJ, USA).
Cell culture. THP-1 cells were obtained from American Type Culture Collection (Manassas, VA, USA), and cultured in RPMI1640 medium (Life Technologies, CA, USA) containing 10% fetal calf serum (FCS), 100 U/ml penicillin and 100 mg/ml streptomycin.
Differentiation of THP-1 cells. Differentiation of THP-1 cells to macrophages was triggered by addition of PMA (50 ng/ml), followed by overnight incubation. After Figure 7 | Schematic representation of the LPS-TLR4 and IL-32-PR3-PAR2 signaling pathways. Once LPS from Gram-negative bacteria is recognized by TLR4, the TLR4-MyD88 pathway is triggered, and early-phase TNFa expression is initiated through the activation of NF-kB and MAPKs. Activation of PKCe results in activation of TRAM-TRIF, which is responsible for late-phase TNFa and type I interferon (i.e., IFN-a/b) expression. Concurrently, IL32c binds to PR3 and activates PAR2. PAR2-Ras and -TRIF pathways potentially induce TNFa expression, and the latter pathway in particular induces type I interferon expression via IRF3/7. At that time, TAG is synthesized to terminate TLR4-TRIF signaling, with TRIF preferentially recruited to PAR2 instead. Following LPS-induced TNFa expression mainly through TLR4, LPS-induced IL-32c-PAR2 signaling gradually increases type I interferon expression, which potentially translates innate to adaptive immunity, or ceases a series of LPS-induced acute inflammation. washing twice, the cells were incubated with RPMI1640 for 48 h. These differentiated THP-1 cells were subjected to the all experiments.
FLISP. FLISPH was reagent for measurement of the activities of serine proteases and purchased from Immunochemistry Technologies (Bloomington, MN, USA). Experiments with THP-1 were performed according to the instructions from the manufacturer and fluorescence spectrometry was undertaken using Power Scan HT (DS Pharma Biomedical, Osaka, Japan).
Construction and transfection of small interfering RNA (siRNA). Stealth RNA interference (RNAi) against multiple molecules and each Stealth RNAi-negative control, which was one or a few bases different from original RNAi sequences, were purchased from Life Technologies Japan (Tokyo, Japan). Sequences of the Stealth RNAi used in this study are presented in Supplementary Table 1 . THP-1 cells were transfected with 40 nM siRNA using Lipofectamine 2000 (Life Technologies) according to the instructions from the manufacturer, and then treated at 24 h posttransfection. Specific gene silencing was confirmed by real-time PCR (Figs. S1-S4) .
Stimulation of cells. THP-1 cells (1 3 10 5 cells) were cultured with LPS (100 ng/ml or 1 mg/ml), zymosan (10 or 100 mg/ml), poly (I:C) (10 or 100 mg/ml), imiquimod (10 or 100 mg/ml), and CpG-B DNA (10 or 100 mM) for 6 h, then the amount of IL-32 was measured by real-time PCR. As to cells culturing with LPS, zymosan and poly (I:C), the amount of IL-32 protein was measured by specific ELISA. THP-1 cells (1 3 10 5 cells) were cultured with LPS (100 ng/ml) for 6, 12, or 24 h and the amount of produced IL-32 was measured by real-time PCR and specifc ELISA. Statistical analysis. Results are reported as mean 6 standard deviation (SD). Statistical analysis was undertaken using a two-tailed Student's t-test or one-way ANOVA. Differences were considered statistically significant at the p , 0.05 level. All experiments were performed in four times.
